Inside Startup Investing with Chris Lustrino · 2026-05-28 · 25 min
On this episode of Inside Startup Investing , Chris Lustrino speaks with Dr. Michael Wyand, CEO of Oxeia Biopharma , a clinical-stage biotech company developing a potential breakthrough treatment for concussions and persistent concussion symptoms. Oxeia is leveraging ghrelin, a naturally occurring hormone involved in brain energy regulation and neural repair, to help heal the inflammation and cellular damage caused by traumatic brain injuries. With promising Phase 2a data showing an 85% responder rate among treated patients, the company is pursuing what could become the first FDA-approved pharmaceutical treatment specifically targeting concussion recovery. Chris and Michael discuss the science behind concussions, how brain damage occurs after impact, why “just rest” has remained the standard of care for decades, and how Oxeia’s therapy could fundamentally change the treatment landscape for athletes, veterans, and millions of patients suffering from lingering neurological symptoms.
Lumida Wealth CEO Ram Ahluwalia on the Future of AI-Powered Wealth Management57 / 100TerraCycle CEO Tom Szaky on Building a Profitable Circular Economy BusinessWhat It Takes to Build a Flying Car CompanyHow Chris Graebe Built a Portfolio of Startup WinnersDealMaker CEO Rebecca Kacaba on the Rise of Retail Investors